Pegdinetanib
Pegdinetanib Uses, Dosage, Side Effects, Food Interaction and all others data.
CT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis pathway. As a result, CT-322 blocks all known ligands for VEGFR-2.
| Trade Name | Pegdinetanib |
| Generic | Pegdinetanib |
| Pegdinetanib Other Names | Pegdinetanib |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.
How Pegdinetanib works
CT-322 specifically inhibits VEGFR-2 activation by its ligands VEGF-A, VEGF-C, and VEGF-D. In preclinical studies, this cell-surface receptor drives angiogenesis (growth of new blood vessels) in solid tumors, and CT-322 inhibits the tumorgenic effect of VEGFR-2 in preclinical models. CT-322 was designed using the PROfusion(TM) System, Adnexus' patented product design engine.
Innovators Monograph
You find simplified version here Pegdinetanib
